Mesothelioma epidemiology and demographics: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| (2 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Mesothelioma}} | {{Mesothelioma}} | ||
{{CMG}}{{AE}}{{PSD}}, {{SR}} | {{CMG}}{{AE}}{{FA}}{{PSD}}, {{SR}} | ||
==Overview== | ==Overview== | ||
Mesothelioma is a rare disease which accounts for 5-28% of all malignancies that involve the pleura. | Mesothelioma is a rare disease which accounts for 5-28% of all malignancies that involve the pleura. The [[incidence]] of mesothelioma is estimated to be 3,000 cases annually. The [[incidence]] of [[pleural]] mesothelioma is approximately 1 per 100,000 individuals in the United States. Males are more commonly affected with mesothelioma than females. The male to female ratio is approximately 3 to 1. The [[incidence]] of mesothelioma increases with age; the median age at diagnosis for [[pleural]] mesothelioma and [[peritoneal]] mesothelioma are 74 years and 68 years, respectively. There is no racial predilection to mesothelioma. | ||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
===Prevalence=== | ===Prevalence=== | ||
*Mesothelioma is a rare disease which accounts for 5-28% of all malignancies that involve the pleura.<ref name=epidemiologymesothelioma1>Epidemiology of mesothelioma. Dr Bruno Di Muzio and A.Prof Frank Gaillard et al. Radiopaedia 2016. http://radiopaedia.org/articles/mesothelioma. Accessed on February 8, 2016</ref> | *Mesothelioma is a rare disease which accounts for 5-28% of all malignancies that involve the pleura.<ref name="epidemiologymesothelioma1">Epidemiology of mesothelioma. Dr Bruno Di Muzio and A.Prof Frank Gaillard et al. Radiopaedia 2016. http://radiopaedia.org/articles/mesothelioma. Accessed on February 8, 2016</ref> | ||
===Incidence=== | ===Incidence=== | ||
*The incidence of mesothelioma is estimated to be 3,000 cases annually.<ref name="A.X.2012">Philip A. Rascoe, Xiaobo X. Cao and W. Roy Smythe (2012). Molecular Pathogenesis of Malignant Pleural Mesothelioma, Mesotheliomas - Synonyms and Definition, Epidemiology, Etiology, Pathogenesis, Cyto-Histopathological Features, Clinic, Diagnosis, Treatment, Prognosis, Dr Alexander Zubritsky (Ed.), ISBN: 978-953-307-845-8, InTech, Available from: http://www.intechopen.com/books/mesotheliomas-synonyms-and-definition-epidemiology-etiology-pathogenesis-cyto-histopathological-features-clinic-diagnosis-treatment-prognosis/molecular-pathogenesis-of-malignant-pleural-mesothelioma</ref> | *The [[incidence]] of mesothelioma is estimated to be 3,000 cases annually.<ref name="A.X.2012">Philip A. Rascoe, Xiaobo X. Cao and W. Roy Smythe (2012). Molecular Pathogenesis of Malignant Pleural Mesothelioma, Mesotheliomas - Synonyms and Definition, Epidemiology, Etiology, Pathogenesis, Cyto-Histopathological Features, Clinic, Diagnosis, Treatment, Prognosis, Dr Alexander Zubritsky (Ed.), ISBN: 978-953-307-845-8, InTech, Available from: http://www.intechopen.com/books/mesotheliomas-synonyms-and-definition-epidemiology-etiology-pathogenesis-cyto-histopathological-features-clinic-diagnosis-treatment-prognosis/molecular-pathogenesis-of-malignant-pleural-mesothelioma</ref> | ||
*The incidence of pleural mesothelioma is approximately 1 per 100,000 individuals in the United States.<ref name="Saint-PierrePease2015">{{cite journal|last1=Saint-Pierre|first1=Mathieu D.|last2=Pease|first2=Christopher|last3=Mithoowani|first3=Hamid|last4=Zhang|first4=Tinghua|last5=Nicholas|first5=Garth A.|last6=Laurie|first6=Scott A.|last7=Wheatley-Price|first7=Paul|title=Malignant Pleural Mesothelioma Outcomes in the Era of Combined Platinum and Folate Antimetabolite Chemotherapy|journal=Lung Cancer International|volume=2015|year=2015|pages=1–7|issn=2090-3197|doi=10.1155/2015/590148}}</ref> | *The [[incidence]] of pleural mesothelioma is approximately 1 per 100,000 individuals in the United States.<ref name="Saint-PierrePease2015">{{cite journal|last1=Saint-Pierre|first1=Mathieu D.|last2=Pease|first2=Christopher|last3=Mithoowani|first3=Hamid|last4=Zhang|first4=Tinghua|last5=Nicholas|first5=Garth A.|last6=Laurie|first6=Scott A.|last7=Wheatley-Price|first7=Paul|title=Malignant Pleural Mesothelioma Outcomes in the Era of Combined Platinum and Folate Antimetabolite Chemotherapy|journal=Lung Cancer International|volume=2015|year=2015|pages=1–7|issn=2090-3197|doi=10.1155/2015/590148}}</ref> | ||
*The incidence of pleural mesothelioma is approximately 1.2 per 100,000 individuals in Canada.<ref name="Saint-PierrePease2015">{{cite journal|last1=Saint-Pierre|first1=Mathieu D.|last2=Pease|first2=Christopher|last3=Mithoowani|first3=Hamid|last4=Zhang|first4=Tinghua|last5=Nicholas|first5=Garth A.|last6=Laurie|first6=Scott A.|last7=Wheatley-Price|first7=Paul|title=Malignant Pleural Mesothelioma Outcomes in the Era of Combined Platinum and Folate Antimetabolite Chemotherapy|journal=Lung Cancer International|volume=2015|year=2015|pages=1–7|issn=2090-3197|doi=10.1155/2015/590148}}</ref> | *The [[incidence]] of pleural mesothelioma is approximately 1.2 per 100,000 individuals in Canada.<ref name="Saint-PierrePease2015">{{cite journal|last1=Saint-Pierre|first1=Mathieu D.|last2=Pease|first2=Christopher|last3=Mithoowani|first3=Hamid|last4=Zhang|first4=Tinghua|last5=Nicholas|first5=Garth A.|last6=Laurie|first6=Scott A.|last7=Wheatley-Price|first7=Paul|title=Malignant Pleural Mesothelioma Outcomes in the Era of Combined Platinum and Folate Antimetabolite Chemotherapy|journal=Lung Cancer International|volume=2015|year=2015|pages=1–7|issn=2090-3197|doi=10.1155/2015/590148}}</ref> | ||
*The incidence of mesothelioma has decreased over several decades in the United States coincident with diminishing occupational [[asbestos]] exposure and has remained stable since 2003.<ref name="ThomasChen2015">{{cite journal|last1=Thomas|first1=Anish|last2=Chen|first2=Yuanbin|last3=Yu|first3=Tinghui|last4=Gill|first4=Ammara|last5=Prasad|first5=Vinay|title=Distinctive clinical characteristics of malignant mesothelioma in young patients|journal=Oncotarget|volume=6|issue=18|year=2015|pages=16766–16773|issn=1949-2553|doi=10.18632/oncotarget.4414}}</ref> | *The [[incidence]] of mesothelioma has decreased over several decades in the United States coincident with diminishing occupational [[asbestos]] exposure and has remained stable since 2003.<ref name="ThomasChen2015">{{cite journal|last1=Thomas|first1=Anish|last2=Chen|first2=Yuanbin|last3=Yu|first3=Tinghui|last4=Gill|first4=Ammara|last5=Prasad|first5=Vinay|title=Distinctive clinical characteristics of malignant mesothelioma in young patients|journal=Oncotarget|volume=6|issue=18|year=2015|pages=16766–16773|issn=1949-2553|doi=10.18632/oncotarget.4414}}</ref> | ||
===Age=== | ===Age=== | ||
*Males are more commonly affected with mesothelioma than females. The male to female ratio is approximately 3 to 1.<ref name=epidemiologymesothelioma1>Mesothelioma. CGMH.ORG 2016. https://www1.cgmh.org.tw/intr/intr5/c6700/OBGYN/f/web/Mesothelioma/index.htm. Accessed on February 15, 2016</ref> | *Males are more commonly affected with mesothelioma than females. The male to female ratio is approximately 3 to 1.<ref name="epidemiologymesothelioma1">Mesothelioma. CGMH.ORG 2016. https://www1.cgmh.org.tw/intr/intr5/c6700/OBGYN/f/web/Mesothelioma/index.htm. Accessed on February 15, 2016</ref> | ||
*The incidence of mesothelioma increases with age; the median age at diagnosis for pleural mesothelioma and peritoneal mesothelioma are 74 years and 68 years, respectively.<ref name="ThomasChen2015">{{cite journal|last1=Thomas|first1=Anish|last2=Chen|first2=Yuanbin|last3=Yu|first3=Tinghui|last4=Gill|first4=Ammara|last5=Prasad|first5=Vinay|title=Distinctive clinical characteristics of malignant mesothelioma in young patients|journal=Oncotarget|volume=6|issue=18|year=2015|pages=16766–16773|issn=1949-2553|doi=10.18632/oncotarget.4414}}</ref> | *The [[incidence]] of mesothelioma increases with age; the median age at diagnosis for [[pleural]] mesothelioma and peritoneal mesothelioma are 74 years and 68 years, respectively.<ref name="ThomasChen2015">{{cite journal|last1=Thomas|first1=Anish|last2=Chen|first2=Yuanbin|last3=Yu|first3=Tinghui|last4=Gill|first4=Ammara|last5=Prasad|first5=Vinay|title=Distinctive clinical characteristics of malignant mesothelioma in young patients|journal=Oncotarget|volume=6|issue=18|year=2015|pages=16766–16773|issn=1949-2553|doi=10.18632/oncotarget.4414}}</ref> | ||
===Race=== | ===Race=== | ||
*There is no racial predilection to mesothelioma.<ref name=epidemiologymesothelioma1>Mesothelioma. CGMH.ORG 2016. https://www1.cgmh.org.tw/intr/intr5/c6700/OBGYN/f/web/Mesothelioma/index.htm. Accessed on February 15, 2016</ref> | *There is no racial predilection to mesothelioma.<ref name="epidemiologymesothelioma1">Mesothelioma. CGMH.ORG 2016. https://www1.cgmh.org.tw/intr/intr5/c6700/OBGYN/f/web/Mesothelioma/index.htm. Accessed on February 15, 2016</ref> | ||
==References== | ==References== | ||
| Line 36: | Line 36: | ||
[[Category:Oncology]] | [[Category:Oncology]] | ||
[[Category:Mature chapter]] | [[Category:Mature chapter]] | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
Latest revision as of 16:09, 25 April 2018
|
Mesothelioma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Mesothelioma epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Mesothelioma epidemiology and demographics |
|
Risk calculators and risk factors for Mesothelioma epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Fatima Shaukat, MD [2]Parminder Dhingra, M.D. [3], Sujit Routray, M.D. [4]
Overview
Mesothelioma is a rare disease which accounts for 5-28% of all malignancies that involve the pleura. The incidence of mesothelioma is estimated to be 3,000 cases annually. The incidence of pleural mesothelioma is approximately 1 per 100,000 individuals in the United States. Males are more commonly affected with mesothelioma than females. The male to female ratio is approximately 3 to 1. The incidence of mesothelioma increases with age; the median age at diagnosis for pleural mesothelioma and peritoneal mesothelioma are 74 years and 68 years, respectively. There is no racial predilection to mesothelioma.
Epidemiology and Demographics
Prevalence
- Mesothelioma is a rare disease which accounts for 5-28% of all malignancies that involve the pleura.[1]
Incidence
- The incidence of mesothelioma is estimated to be 3,000 cases annually.[2]
- The incidence of pleural mesothelioma is approximately 1 per 100,000 individuals in the United States.[3]
- The incidence of pleural mesothelioma is approximately 1.2 per 100,000 individuals in Canada.[3]
- The incidence of mesothelioma has decreased over several decades in the United States coincident with diminishing occupational asbestos exposure and has remained stable since 2003.[4]
Age
- Males are more commonly affected with mesothelioma than females. The male to female ratio is approximately 3 to 1.[1]
- The incidence of mesothelioma increases with age; the median age at diagnosis for pleural mesothelioma and peritoneal mesothelioma are 74 years and 68 years, respectively.[4]
Race
- There is no racial predilection to mesothelioma.[1]
References
- ↑ 1.0 1.1 1.2 Epidemiology of mesothelioma. Dr Bruno Di Muzio and A.Prof Frank Gaillard et al. Radiopaedia 2016. http://radiopaedia.org/articles/mesothelioma. Accessed on February 8, 2016
- ↑ Philip A. Rascoe, Xiaobo X. Cao and W. Roy Smythe (2012). Molecular Pathogenesis of Malignant Pleural Mesothelioma, Mesotheliomas - Synonyms and Definition, Epidemiology, Etiology, Pathogenesis, Cyto-Histopathological Features, Clinic, Diagnosis, Treatment, Prognosis, Dr Alexander Zubritsky (Ed.), ISBN: 978-953-307-845-8, InTech, Available from: http://www.intechopen.com/books/mesotheliomas-synonyms-and-definition-epidemiology-etiology-pathogenesis-cyto-histopathological-features-clinic-diagnosis-treatment-prognosis/molecular-pathogenesis-of-malignant-pleural-mesothelioma
- ↑ 3.0 3.1 Saint-Pierre, Mathieu D.; Pease, Christopher; Mithoowani, Hamid; Zhang, Tinghua; Nicholas, Garth A.; Laurie, Scott A.; Wheatley-Price, Paul (2015). "Malignant Pleural Mesothelioma Outcomes in the Era of Combined Platinum and Folate Antimetabolite Chemotherapy". Lung Cancer International. 2015: 1–7. doi:10.1155/2015/590148. ISSN 2090-3197.
- ↑ 4.0 4.1 Thomas, Anish; Chen, Yuanbin; Yu, Tinghui; Gill, Ammara; Prasad, Vinay (2015). "Distinctive clinical characteristics of malignant mesothelioma in young patients". Oncotarget. 6 (18): 16766–16773. doi:10.18632/oncotarget.4414. ISSN 1949-2553.